Edition:
United States

Epizyme Inc (EPZM.OQ)

EPZM.OQ on NASDAQ Stock Exchange Global Select Market

12.65USD
12 Dec 2017
Change (% chg)

$-0.20 (-1.56%)
Prev Close
$12.85
Open
$12.80
Day's High
$12.95
Day's Low
$12.50
Volume
103,701
Avg. Vol
152,031
52-wk High
$20.40
52-wk Low
$9.35

Select another date:

Thu, Sep 14 2017

BRIEF-Epizyme announces pricing of public offering of common stock

* Epizyme announces pricing of public offering of common stock

BRIEF-Epizyme reports Q2 loss of $0.48/shr

* Epizyme reports second quarter 2017 financial results and clinical and business progress

BRIEF-US Oncology Research and Epizyme establish collaboration to identify non-hodgkin lymphoma patients with EZH2 mutations

* US Oncology Research and Epizyme establish collaboration to identify non-hodgkin lymphoma patients with EZH2 mutations

BRIEF-Epizyme announces Tazemetostat to be evaluated in NCI-COG pediatric MATCH trial

* Epizyme announces Tazemetostat to be evaluated in NCI’s recently initiated NCI-COG pediatric MATCH trial Source text for Eikon: Further company coverage:

BRIEF-Epizyme expands clinical collaboration with Genentech

* Epizyme expands clinical collaboration to study tazemetostat and tecentriq® combination in nsclc

BRIEF-Epizyme announces tazemetostat granted orphan drug designation

* Epizyme announces tazemetostat granted orphan drug designation for the treatment of soft tissue sarcoma Source text for Eikon: Further company coverage:

BRIEF-Epizyme reports positive interim data from Phase 2 trial for tazemetostat

* Epizyme reports positive interim data from Phase 2 trial for tazemetostat in relapsed or refractory follicular lymphoma and dlbcl patients

Select another date: